Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (HBIO) delivers specialized scientific instruments that power breakthroughs in life sciences research and drug discovery. This dedicated news hub provides investors and researchers with essential updates on corporate developments shaping the preclinical research sector.
Access authoritative coverage of HBIO's financial announcements, product innovations, and strategic initiatives. Our curated collection includes earnings reports, regulatory filings, technology launches, and partnership updates – all critical for assessing the company's role in advancing laboratory science worldwide.
Key updates span electrophysiology platform enhancements, telemetry system deployments, and organoid research advancements. Track how HBIO's global distribution network supports pharmaceutical developers and academic institutions through reliable instrumentation solutions.
Bookmark this page for streamlined monitoring of Harvard Bioscience's operational milestones. Verify research trends and corporate health through primary-source updates from the company's investor relations communications and verified media coverage.
Harvard Bioscience (NASDAQ: HBIO) announced the resignation of CFO and Treasurer Jennifer Cote, effective upon the filing of the Company's Q1 2025 10-Q report, expected by May 12, 2025. The company has appointed Mark Frost as Interim CFO and Treasurer.
Frost, who has been consulting for HBIO since January 2025, brings over 30 years of financial and executive management experience. His previous roles include CFO positions at Fathom, Argon Medical Devices, Analogic, AngioDynamics, and AMRI. He began his career at General Electric and holds a BA in International Relations and Economics from Colgate University.
CEO Jim Green expressed confidence in Frost's capabilities to lead the finance team in the current challenging market environment, while acknowledging Cote's contributions, particularly in leading the recent ERP system consolidation project.
Harvard Bioscience (Nasdaq: HBIO) has announced its participation in two major investor conferences in March 2025. The company's leadership team, including Chairman and CEO Jim Green and CFO Jennifer Cote, will attend:
1. The 37th Annual Roth Conference (March 16-18, 2025) at the Laguna Cliffs Marriott Resort in Dana Point, CA. Management will conduct one-on-one meetings and participate in a Fireside Chat on March 17th at 10 a.m. PT.
2. The KeyBanc Capital Markets Healthcare Forum, a virtual event on March 19, 2025, featuring one-on-one meetings and a Fireside Chat with Paul Knight at 3:45 p.m. ET.
Both events will be webcast live on the company's investor relations website.
Harvard Bioscience (HBIO) reported Q4 2024 revenues of $24.6 million, down from $28.2 million in Q4 2023. The company achieved a Q4 gross margin of 57.1% and posted a minimal net income of $18,000, improving from a $1.8 million loss in Q4 2023.
For full-year 2024, revenues declined to $94.1 million from $112.3 million in 2023, with a gross margin of 58.2%. The company recorded a net loss of $12.4 million for 2024, compared to a $3.4 million loss in 2023. The decline was attributed to challenging global market conditions and reduced spending by CROs, distributors, and academic institutions.
Looking ahead, HBIO projects Q1 2025 revenues between $19-21 million with gross margins of 56-58%, citing uncertainty in NIH funding and academic research purchasing.
Harvard Bioscience (HBIO) will showcase its latest product innovations at the Society of Toxicology conference in Orlando from March 17-20, 2025. The company is presenting three major solutions:
1. The expanded SoHo™ Implantable Real-Time Telemetry Platform, which includes new biopotential monitoring devices for neurotoxicity and cardiovascular toxicology studies. The platform integrates with Ponemah data management system to automate data collection and analysis.
2. The VivaMARS™ Activity Monitoring System, a GLP-compliant platform for real-time behavioral analysis, aimed at CROs and pharmaceutical companies for neuropharmacology applications.
3. The Mesh MEA™ Organoid Platform, designed for real-time electrophysiological readings from living organoids, supporting research, safety pharmacology, and toxicology studies. The NIH has recently adopted this system for advanced neuro organoid research.
Harvard Bioscience (NASDAQ: HBIO) has announced it will release its financial results for Q4 2024 before market opening on March 12, 2025. The company will host a conference call at 8:00 AM ET on the same day to discuss the results.
Interested participants who wish to ask questions during the call must pre-register to receive dial-in numbers and a unique PIN. An audio-only webcast option will also be available through the company's investor website. The earnings release and related presentation materials will be accessible through Harvard Bioscience's Investor Relations section.
Harvard Bioscience (HBIO) has announced its participation in the upcoming Sidoti Micro Cap Virtual Conference on January 22nd, 2025. The company's Chairman and CEO Jim Green, along with CFO Jennifer Cote, will deliver a presentation at 10:00 am ET.
The presentation will be accessible through a live webcast via the investor relations section of Harvard Bioscience's website. Interested parties can view the presentation replay after its conclusion. One-on-one meetings can be arranged through the conference organizers.
Harvard Bioscience (NASDAQ: HBIO) reported Q3 2024 financial results showing revenues of $22.0 million, down from $25.4 million in Q3 2023. The company posted a net loss of $(4.8) million compared to $(1.2) million in the same period last year. Gross margin remained stable at 58.1%, while Adjusted EBITDA decreased to $1.3 million from $2.2 million.
The company completed migration to a single US enterprise resource planning system and implemented cost reduction actions expected to save $1 million quarterly starting Q4. For Q4 2024, HBIO expects revenues between $23-26 million with gross margins of 59-60% and adjusted EBITDA margin in mid-teens.
Harvard Bioscience (Nasdaq: HBIO) has scheduled its third quarter 2024 financial results announcement for November 7, 2024, before market opening. The company will host a conference call at 8:00 AM ET to discuss the results. Participants wanting to ask questions must pre-register to receive dial-in information and a PIN. An audio-only webcast option is also available through the company's investor website, where the earnings release and related presentation materials will be accessible.
Harvard Bioscience (Nasdaq: HBIO) will showcase its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting in Chicago. Key highlights include:
1. Mesh MEA™ microelectrode array system: Captures electrophysiology signals from inside organoids in real-time, providing new insights into neural dynamics and brain disorders.
2. SoHo™ implantable telemetry platform: Allows data collection from multiple small animal models in a shared housing environment, integrated with the Ponemah™ data management platform.
3. VivaMARS™ activity monitoring system: Offers real-time behavioral testing for neurological research and neuropharmacology studies, reducing operating expenses and test cycle times.
The company will also display its new Heka™ patch clamp amplifiers and other products supporting in vitro and in vivo neuroscience research. Harvard Bioscience will exhibit at booth #925 at the McCormick Place Convention Center from October 6-9, 2024.
Harvard Bioscience (Nasdaq: HBIO) is showcasing its latest product innovations at the Safety Pharmacology Society Annual Meeting from September 22-25, 2024, in San Diego. The company is presenting several key solutions:
1. DSI Ponemah Data Management Platform: An integrated preclinical solution for managing and analyzing data from various studies.
2. SoHo Implantable Real-Time Telemetry: A system for small animal models, enabling longer duration studies and increased testing throughput.
3. VivaMARS Activity Monitoring System: A platform for real-time, high-throughput behavioral testing in neuropharmacology safety and toxicology studies.
4. MCS Mesh MEA Organoid Platform: Designed for organoid applications in research, safety pharmacology, and toxicology, allowing real-time electrophysiology measurements inside living organoids.
